Pivalde, with my limited understanding of that paper, I think...

Pivalde, with my limited understanding of that paper, I think PBT2 could be used as an adjuvant with any antibiotic. As I don't hold stock in this company I do not intend to read the patents to see if it is covered for use as an antibiotic, which basically that use is, along with a zinc supplement, which I believe is OTC(over the counter). Prana handed the drug over for screening in good faith the UQ would live up to their statement that any discoveries that came out of the process would belong to the donor company(prana). The inventor of the drug is Prana(Barnham). The patent should be for use with all antibiotics as I see it. There are other chelators out there, so Prana really should get a move on.
It looks like PBT2 came to the fore of the hit compounds at UQ, and then the three institutions investigated the MOA and then published, so you have to think that UQ discovered the initial hit quite some time ago.
Note the patent also covers compositions containing PBT2
[Patents Support Pipeline Opportunities for PBT2 in AD and HDAugust 24, 2010: 08:48 AM ETPrana Biotechnology (NASDAQ: PRAN) (ASX: PBT) today announced that it has secured key PBT2 patents in Europe and the United States.The United States Patent and Trademark Office (USPTO) has Granted a composition of matter patent for selected 8-hydroxyquinoline compounds, including its lead clinical asset, PBT2, in the United States. The patent titled '8-Hydroxyquinoline derivatives' also covers pharmaceutical compositions containing PBT2 and selected 8-hydroxyquinoline compounds.]
I guess that covers combination drugs. 
https://money.cnn.com/news/newsfeeds/articles/marketwire/0654817.htm